Drug Profile
Eos 002
Alternative Names: Eos-002Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Eos Biosciences
- Class Antineoplastics; Diagnostic agents; Imaging agents
- Mechanism of Action Free radical stimulants; Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Injection)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA (IV, Injection)
- 13 Sep 2017 Eos 002 is covered by patent protection in USA and US PTO grants patent for Eos 002 for Breast Cancer